| Literature DB >> 32630145 |
Samuel R Moxon1, Miguel J S Ferreira2, Patricia Dos Santos3, Bogdan Popa2, Antonio Gloria4, Ramaz Katsarava5, David Tugushi5, Armenio C Serra3, Nigel M Hooper1, Susan J Kimber6, Ana C Fonseca3, Marco A N Domingos6,7.
Abstract
Degeneration of articular cartilage (AC) is a common healthcare issue that can result in significantly impaired function and mobility for affected patients. The avascular nature of the tissue strongly burdens its regenerative capacity contributing to the development of more serious conditions such as osteoarthritis. Recent advances in bioprinting have prompted the development of alternative tissue engineering therapies for the generation of AC. Particular interest has been dedicated to scaffold-based strategies where 3D substrates are used to guide cellular function and tissue ingrowth. Despite its extensive use in bioprinting, the application of polycaprolactone (PCL) in AC is, however, restricted by properties that inhibit pro-chondrogenic cell phenotypes. This study proposes the use of a new bioprintable poly(ester urea) (PEU) material as an alternative to PCL for the generation of an in vitro model of early chondrogenesis. The polymer was successfully printed into 3D constructs displaying adequate substrate stiffness and increased hydrophilicity compared to PCL. Human chondrocytes cultured on the scaffolds exhibited higher cell viability and improved chondrogenic phenotype with upregulation of genes associated with type II collagen and aggrecan synthesis. Bioprinted PEU scaffolds could, therefore, provide a potential platform for the fabrication of bespoke, pro-chondrogenic tissue engineering constructs.Entities:
Keywords: 3D bioprinting; cartilage repair; poly(ester urea); scaffold design; tissue engineering
Year: 2020 PMID: 32630145 PMCID: PMC7408263 DOI: 10.3390/polym12071478
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1A representation of the chemical synthesis of PEU including (a) synthesis of bis(α-amino acid) ester from l-leucine and 1,6-hexanediol and (b) the reaction between bis(α-amino acid) ester from l-leucine and 1,6-hexanediol and triphosgene to yield the l-leucine-based PEU.
Optimised set of process parameters used for the printing of PCL and PEU scaffolds. Parameters are denoted as deposition velocity (DV), slice thickness (ST), liquefier temperature (LT), extrusion pressure (EP) and screw rotation velocity (SRV).
| Process Parameters | |||||
|---|---|---|---|---|---|
| DV (mm/s) | ST (μm) | LT (°C) | EP (bar) | SRV (rpm) | |
|
| 20 | 280 | 90 | 5 | 11 |
|
| 22 | 280 | 125 | 5 | 8 |
Figure 2Spectroscopic data of the synthesised PEU demonstrating (a) the FTIR spectrum of PEU and (b) the 1H NMR spectrum of l-leucine-based PEU.
Figure 3SEM micrographs of 3D printed scaffolds. (a) PCL scaffold top view; (b) PEU scaffold top view; (c) PCL scaffold cross-sectional view; (d) PEU scaffold cross-sectional view.
Figure 4Mechanical data for 3D-bioprinted scaffolds of PEU and PCL (n = 5). (a) Nanoindentation data demonstrating the hardness of each scaffold as a function of the applied load, (b) compression data for each scaffold represented by stress–strain curves.
Figure 5Average water contact angles for films and filaments of PCL and PEU scaffolds (* indicates p < 0.001, PEU vs. PCL; error bars represent standard error of mean, n = 5).
Figure 6The biological response of TC28a2 human chondrocytes to PEU and PCL scaffolds. (a) Fluorescence confocal microscopy images of chondrocytes seeded onto PEU/PCL scaffolds and stained with phalloidin (actin) and DAPI (nuclei); (b) absorbance at 570 nm of chondrocyte culture media treated with 0.1 mg/mL resazurin after 7, 14 and 21 days on PEU and PCL scaffolds; (c–e) relative expression of COL1A1, aggrecan and COL2A1 by chondrocytes seeded on PEU and PCL scaffolds at day 7, 14 and 21, respectively (* indicates p < 0.05, PEU vs. PCL; error bars represent standard error of the mean, n = 3).